Palumbo A et al. A Phase 3 study evaluating the efficacy and safety of lenalidomide (len) combined with melphalan and prednisone followed by continuous lenalidomide maintenance (MPR-R) in patients (pts) ≥ 65 years (yrs) with newly diagnosed multiple myeloma (NDMM): Updated results for pts aged 65-75 yrs enrolled in MM-015. Proc ASH 2011;Abstract 475.

Dr Lonial is Vice Chair of Clinical Affairs and Director of Translational Research at the Emory University School of Medicine’s Winship Cancer Institute in Atlanta, Georgia.

Dr Richardson is Associate Professor of Medicine at Harvard Medical School and Clinical Director of the Jerome Lipper Center for Multiple Myeloma at Dana-Farber Cancer Institute in Boston, Massachusetts.